Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease Clinical Trial

Official title:
A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease.

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the superiority of efficacy of TAK-438, once daily (QD), to placebo in patients with non-erosive gastroesophageal reflux disease.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Gastroesophageal Reflux
Non-erosive Gastroesophageal Reflux Disease

Clinical Trial Details

NCT number	NCT01474369
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	December 2011
Completion date	February 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00165646` - A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease	Phase 3
Completed	`NCT02954848` - Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)	Phase 3
Completed	`NCT00165672` - A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease	Phase 3
Completed	`NCT01047800` - Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial	N/A
Recruiting	`NCT03811080` - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease	Phase 3